| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Chief Patient Officer | EVP Strat Comm, Gi Pub Policy | EVP Strat Comm, Gl Pub Policy
1 company
Gerberding Julie L. is an EVP, Chief Patient Officer at Merck & Co., Inc.. Recent SEC Form 4 filings include 0 buys and 8 sells.
Estimated insider holdings value: $5.5M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 1, 2021 | MRK Merck & Co., Inc. | EVP, Chief Patient Officer | Sale+OE | 96,270 | $87.91 | $8,462,681.74 | -71.1% | -6.4% | +17.6% | |
| Jul 17, 2020 | MRK Merck & Co., Inc. | EVP Strat Comm, Gi Pub Policy | Sale+OE | 36,285 | $80.00 | $2,902,976.29 | -33.7% | - | - | |
| Jan 13, 2020 | MRK Merck & Co., Inc. | EVP Strat Comm, Gi Pub Policy | Sale+OE | 102,073 | $89.34 | $9,118,864.98 | -73.4% | - | - | |
| Nov 7, 2018 | MRK Merck & Co., Inc. | EVP Strat Comm, Gl Pub Policy | Sale+OE | 36,218 | $75.14 | $2,721,348.08 | -43.9% | - | - | |
| May 15, 2018 | MRK Merck & Co., Inc. | EVP Strat Comm, Gl Pub Policy | Sell | 9,972 | $59.66 | $594,963.42 | -17.9% | - | - | |
| Nov 7, 2016 | MRK Merck & Co., Inc. | EVP Strat Comm, Gl Pub Policy | Sale+OE | 85,523 | $60.02 | $5,133,329.92 | -68.6% | - | - | |
| May 8, 2015 | MRK Merck & Co., Inc. | EVP Strat Comm, Gl Pub Policy | Sale+OE | 38,368 | $60.99 | $2,339,949.22 | -54.5% | - | - |